Display Settings:

Format

Send to:

Choose Destination

    Clin Infect Dis. 2003 Sep 1;37(5):e57-62. Epub 2003 Aug 13.

    Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected].

    Blanchard JN, Wohlfeiler M, Canas A, King K, Lonergan JT.

    Division of General Internal Medicine, University of California, San Diego Medical Center, 92103-8681, USA. jblanchard@ucsd.edu

    Erratum in:

    • Clin Infect Dis. 2003 Oct 1;37(7):995.

    Pancreatitis occurs in up to 7% of patients infected with human immunodeficiency virus who are treated with standard doses of didanosine. Tenofovir disoproxil fumarate increases the plasma levels of didanosine and, thus, the combination of these agents may increase the risk of pancreatitis. Four cases of pancreatitis that occurred during administration of this drug combination are examined, including 1 that resulted in death.

    PMID: 12942419 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read Click here to read Click here to read Click here to read

    Patient drug information